620 related articles for article (PubMed ID: 22795564)
21. High throughput screening identified a substituted imidazole as a novel RANK pathway-selective osteoclastogenesis inhibitor.
Chen T; Knapp AC; Wu Y; Huang J; Lynch JS; Dickson JK; Lawrence RM; Feyen JH; Agler ML
Assay Drug Dev Technol; 2006 Aug; 4(4):387-96. PubMed ID: 16945012
[TBL] [Abstract][Full Text] [Related]
22. Monosodium Urate in the Presence of RANKL Promotes Osteoclast Formation through Activation of c-Jun N-Terminal Kinase.
Choe JY; Park KY; Kim SK
Mediators Inflamm; 2015; 2015():597512. PubMed ID: 26347587
[TBL] [Abstract][Full Text] [Related]
23. Interleukin 29 inhibits RANKL-induced osteoclastogenesis via activation of JNK and STAT, and inhibition of NF-κB and NFATc1.
Peng Q; Luo A; Zhou Z; Xuan W; Qiu M; Wu Q; Xu L; Kong X; Zhang M; Tan W; Xue M; Wang F
Cytokine; 2019 Jan; 113():144-154. PubMed ID: 30001863
[TBL] [Abstract][Full Text] [Related]
24. Epoxyeicosanoids suppress osteoclastogenesis and prevent ovariectomy-induced bone loss.
Guan H; Zhao L; Cao H; Chen A; Xiao J
FASEB J; 2015 Mar; 29(3):1092-101. PubMed ID: 25466887
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M
Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732
[TBL] [Abstract][Full Text] [Related]
26. The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.
Kim HS; Suh KS; Sul D; Kim BJ; Lee SK; Jung WW
Int J Mol Med; 2012 Feb; 29(2):169-77. PubMed ID: 22038020
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-kappaB signaling pathways.
Choi HJ; Park YR; Nepal M; Choi BY; Cho NP; Choi SH; Heo SR; Kim HS; Yang MS; Soh Y
Eur J Pharmacol; 2010 Jun; 636(1-3):28-35. PubMed ID: 20353769
[TBL] [Abstract][Full Text] [Related]
28. Gymnasterkoreayne F inhibits osteoclast formation by suppressing NFATc1 and DC-STAMP expression.
Kim HJ; Hong J; Jung JW; Kim TH; Kim JA; Kim YH; Kim SY
Int Immunopharmacol; 2010 Nov; 10(11):1440-7. PubMed ID: 20831919
[TBL] [Abstract][Full Text] [Related]
29. RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation.
Sundaram K; Nishimura R; Senn J; Youssef RF; London SD; Reddy SV
Exp Cell Res; 2007 Jan; 313(1):168-78. PubMed ID: 17084841
[TBL] [Abstract][Full Text] [Related]
30. Xanthohumol modulates the expression of osteoclast-specific genes during osteoclastogenesis in RAW264.7 cells.
Suh KS; Rhee SY; Kim YS; Lee YS; Choi EM
Food Chem Toxicol; 2013 Dec; 62():99-106. PubMed ID: 23994090
[TBL] [Abstract][Full Text] [Related]
31. Myricetin prevents titanium particle-induced osteolysis in vivo and inhibits RANKL-induced osteoclastogenesis in vitro.
Wu C; Wang W; Tian B; Liu X; Qu X; Zhai Z; Li H; Liu F; Fan Q; Tang T; Qin A; Zhu Z
Biochem Pharmacol; 2015 Jan; 93(1):59-71. PubMed ID: 25449599
[TBL] [Abstract][Full Text] [Related]
32. FTY720 inhibited proinflammatory cytokine release and osteoclastogenesis induced by Aggregatibacter actinomycetemcomitans.
Yu H; Herbert BA; Valerio M; Yarborough L; Hsu LC; Argraves KM
Lipids Health Dis; 2015 Jul; 14():66. PubMed ID: 26138336
[TBL] [Abstract][Full Text] [Related]
33. Quercetin triggers apoptosis of lipopolysaccharide (LPS)-induced osteoclasts and inhibits bone resorption in RAW264.7 cells.
Guo C; Hou GQ; Li XD; Xia X; Liu DX; Huang DY; Du SX
Cell Physiol Biochem; 2012; 30(1):123-36. PubMed ID: 22759961
[TBL] [Abstract][Full Text] [Related]
34. Sargachromanol G inhibits osteoclastogenesis by suppressing the activation NF-κB and MAPKs in RANKL-induced RAW 264.7 cells.
Yoon WJ; Kim KN; Heo SJ; Han SC; Kim J; Ko YJ; Kang HK; Yoo ES
Biochem Biophys Res Commun; 2013 May; 434(4):892-7. PubMed ID: 23611776
[TBL] [Abstract][Full Text] [Related]
35. Aconine inhibits RANKL-induced osteoclast differentiation in RAW264.7 cells by suppressing NF-κB and NFATc1 activation and DC-STAMP expression.
Zeng XZ; He LG; Wang S; Wang K; Zhang YY; Tao L; Li XJ; Liu SW
Acta Pharmacol Sin; 2016 Feb; 37(2):255-63. PubMed ID: 26592521
[TBL] [Abstract][Full Text] [Related]
36. Neuropeptide FF attenuates RANKL-induced differentiation of macrophage-like cells into osteoclast-like cells.
Sun Y; Chen X; Chen Z; Ma X; Li D; Shang P; Qian A
Arch Oral Biol; 2015 Feb; 60(2):282-92. PubMed ID: 25463906
[TBL] [Abstract][Full Text] [Related]
37. Direct cell-cell contact between periodontal ligament fibroblasts and osteoclast precursors synergistically increases the expression of genes related to osteoclastogenesis.
Bloemen V; Schoenmaker T; de Vries TJ; Everts V
J Cell Physiol; 2010 Mar; 222(3):565-73. PubMed ID: 19927302
[TBL] [Abstract][Full Text] [Related]
38. Apolipoprotein E inhibits osteoclast differentiation via regulation of c-Fos, NFATc1 and NF-κB.
Kim WS; Kim HJ; Lee ZH; Lee Y; Kim HH
Exp Cell Res; 2013 Feb; 319(4):436-46. PubMed ID: 23246654
[TBL] [Abstract][Full Text] [Related]
39. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
[TBL] [Abstract][Full Text] [Related]
40. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]